항생제
Clindamycin

Clindamycin

C. difficile 위험도
High
경구생체이용률
Excellent

Dosing

GPC or susceptible anaerobic infectionB. fragilis, Peptostreptococci, non-perfringens clostridial infection0.6-1.2 g IV #2-41.2-2.7 g IV #2-4

Mild or moderate infectionSevere infection150-300 mg PO q6h300-450 mg PO q6h

No renal dose adjustment

  • Age <1m 16-20 mg/kg IV #3-4

  • Age 1m-16y 20-40 mg/kg IV #3-4

Mild or moderate infectionSevere infection8-16 mg/kg PO #3-416-20 mg/kg PO #3-4

No renal dose adjustment

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dose adjustmentNo data

General Information

Anaerobic infections above the diaphragm, especially dental infection.

Gram-positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta-lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Monitor for diarrhea.

During prolonged therapy, monitor blood count with differential, hepatic and renal functions.

Common

  • Abdominal pain

  • Diarrhea

  • Nausea

Serious

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Erythema multiforme

  • Clostridium difficile colitis

  • Agranulocytosis

  • Muscle relaxants (e.g. atracurium, baclofen, diazepam)

  • St. John's wort

Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor